Date Published 
October 2014 

Page Count 
94

Additional Info 
Single-site, country, and global licenses are multi-user, searchable, and cut-and-paste ready PDFs delivered by e-mail.

  Human Microbiome Bundle 

Human MicroBiome 2016

For Global Licenses, Multi-Reports Orders, Discounts or Order Questions.  

Contact:
Dan Miller
Marketing Associate
781-972-5492 

 


Companies that Purchased this Report

AEC Partners
Agilent Technologies Inc
Bayer Healthcare Pharmaceuticals
BIOASTER
Boehringer Inglelheim Pharmaceuticals
Chalmers University of Technology
Eli Lilly & Co
Johnson & Johnson
Kimberly Clark Corp
Mundipharma Research Ltd
Nestle USA
Philips Research
Takeda Pharmaceutical Co Ltd
Thermo Fisher Scientific Inc
University of Calgary



The Human Microbiome: Biomedical Implications and Birth of a Market - Overview

 

Human-Microbiome

Published in October, 2014, is Insight Pharma Reports’ The Human Microbiome: Biomedical Implications and Birth of a Market. This report covers the evolution of microbiome research and its growth in the commercial market. Specific areas of study include microbial ecology, systems biology, diet, diagnostics, contributions in health and disease, and infectious disease.

Microbiota have become a center for discussion and investigation after research has unraveled the symbiotic relationship between humans and their microbial counterparts, and the impact of the delicate balance of specific microbiota on various diseases. Such diseases include diabetes, Chronic Obstructive Pulmonary Disease (COPD), and Irritable Bowel Diseases (IBD). Understanding how microbiota act as communities, and thus is relation to disease, has been the topic of choice, known as microbial ecology, for several researchers.  It has been demonstrated that when in equilibrium with their environment, microbiota gain benefits from the host, which enables them to provide useful benefits themselves. However, when this balance is disrupted, the repercussions can have a negative impact on human health. For example, the use of antibiotics can lead to vaginal yeast infections in women. This is because antibiotics kill not only the build-up of the infectious bacteria, but also all the other bacteria around it that keeps the control of yeast in check. Destroying these bacteria leads to the overgrowth of yeast and thus yeast infections.

In addition to antibiotics disrupting the microbiome environment, diet is another factor that can pose as a problem. A diet high in carbohydrates can also cause yeast build-up because yeast feed on sugar.  Diet can also create an imbalance in the microbiome environment and jeopardize the symbiotic relationship between the microbiota and the host. A simple difference between consuming plant fats vs. animals fats has been demonstrated to have an effect on the abundance of certain types of bacteria in the gut over others, suggesting that these bacteria may be linked to weight loss and/or gain. In fact, researchers concluded there was a link between people who had animal-based dietary fats, bile acids, and irritable bowel diseases. Due to these findings, researchers are further investigating the relation between microbiota and the impact on various immune pathways, and the influence on obesity and diabetes.

In addition to covering several aspects of the microbiome, the report also includes the impact of this rising field on commercial aspects and product development. Companies covered in this space include:

  • 4D Pharma
  • ActoGenixAOBiome
  • AvidBiotics
  • CIPAC Limited
  • Enterome Bioscience 
  • Human Longevity
  • Metabiomics
  • Microbiome Therapeutics
  • Miomics
  • OmniBiome Therapeutics
  • OptiBiotix
  • Osel Inc
  • OxThera
  • PathoGenetix
  • Rebiotix
  • Ritter Pharmaceuticals
  • Second Genome
  • Seres Health
  • uBiome
  • UCB
  • UC San Francisco
  • Vedanta
  • ViThera Pharmaceuticals
  • Whole Biome

Final features of the report include:

  • In-depth analysis of market data
  • Exclusive interview transcripts with the following experts:
    • Peter DiLaura, President & CEO, Second Genome
    • Colleen Cutcliffe, CEO, Whole Biome
    • James Brown, PhD; Head, Computational Biology; Head, Microbiome Matrix Team; GlaxoSmithKline
    • Jack Gilbert, PhD., Environmental Microbiologist, Assoc. Prof., Department of Ecology & Evolution, Argonne National Laboratory
    • Glenn Tillotson, PhD, Senior Partner, Transcrip Partners, USA
    • Peter P. Lee, MD, Executive Chairman, Osel, Inc.
    • Gregory Kuehn, VP Business Development and Marketing, Metabiomics
    • Stephen Elms, CEO, Miomics Bio-Therapeutics
    • Sydney M. Finegold, M.D., Emeritus Professor of Medicine, and Emeritus Professor of Microbiology, Immunology, and Molecular Biology, UCLA School of Medicine; Staff Physician, Infectious Disease Section, VA Greater Los Angeles Healthcare System